Greenwich Wealth Management LLC decreased its stake in Tilray Brands, Inc. (NASDAQ:TLRY – Free Report) by 90.0% in the fourth quarter, Holdings Channel.com reports. The firm owned 35,370 shares of the company’s stock after selling 318,330 shares during the period. Greenwich Wealth Management LLC’s holdings in Tilray Brands were worth $319,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. AQR Capital Management LLC increased its position in Tilray Brands by 1,839.7% during the first quarter. AQR Capital Management LLC now owns 607,054 shares of the company’s stock valued at $399,000 after acquiring an additional 575,757 shares during the last quarter. XTX Topco Ltd bought a new position in Tilray Brands during the 2nd quarter valued at about $112,000. Cerity Partners LLC grew its holdings in Tilray Brands by 98.5% during the 2nd quarter. Cerity Partners LLC now owns 92,560 shares of the company’s stock valued at $38,000 after purchasing an additional 45,929 shares during the last quarter. Ausdal Financial Partners Inc. purchased a new stake in Tilray Brands in the 2nd quarter worth about $939,000. Finally, Bank of America Corp DE raised its position in Tilray Brands by 26.5% in the 2nd quarter. Bank of America Corp DE now owns 311,810 shares of the company’s stock worth $129,000 after purchasing an additional 65,379 shares during the period. Hedge funds and other institutional investors own 9.35% of the company’s stock.
Tilray Brands Stock Down 5.0%
NASDAQ:TLRY opened at $5.11 on Thursday. The company has a debt-to-equity ratio of 0.19, a current ratio of 2.79 and a quick ratio of 1.66. Tilray Brands, Inc. has a 1-year low of $3.51 and a 1-year high of $23.20. The company has a 50-day moving average of $6.14 and a 200 day moving average of $7.73. The firm has a market cap of $595.57 million, a PE ratio of -0.37 and a beta of 1.88.
Analyst Upgrades and Downgrades
TLRY has been the subject of several recent analyst reports. ATB Cormark Capital Markets dropped their target price on Tilray Brands from $9.50 to $9.00 and set a “sector perform” rating for the company in a research report on Thursday, April 2nd. Wall Street Zen upgraded Tilray Brands from a “sell” rating to a “hold” rating in a report on Saturday, March 21st. TD Cowen decreased their price target on Tilray Brands from $10.00 to $7.00 and set a “buy” rating for the company in a research note on Monday, March 30th. Roth Mkm upgraded Tilray Brands from a “neutral” rating to a “buy” rating and set a $10.00 price objective for the company in a report on Thursday, April 2nd. Finally, Weiss Ratings lowered Tilray Brands from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 13th. Three research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $11.50.
Read Our Latest Stock Analysis on Tilray Brands
Insider Transactions at Tilray Brands
In related news, Director David G. Hopkinson sold 33,556 shares of Tilray Brands stock in a transaction that occurred on Tuesday, April 21st. The shares were sold at an average price of $6.94, for a total transaction of $232,878.64. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.84% of the stock is currently owned by insiders.
Tilray Brands Profile
Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.
Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.
See Also
- Five stocks we like better than Tilray Brands
- Coke’s $10B India IPO Plan Pops the Top on Hidden Value
- FedEx Unboxes Billions in Post-Spinoff Value
- Marvell’s AI Moment Raises a Bigger Question for Amazon and ServiceNow
- Palo Alto Networks Accelerates Growth 31% on AI Demand
Want to see what other hedge funds are holding TLRY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tilray Brands, Inc. (NASDAQ:TLRY – Free Report).
Receive News & Ratings for Tilray Brands Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray Brands and related companies with MarketBeat.com's FREE daily email newsletter.
